Trial Profile
A Phase I/II Trial of AN-152 (AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Zoptarelin doxorubicin (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Feb 2017 Results (n=25) assessing clinical benefit of zoptarelin doxorubicin in castration- and taxane-resistant prostate cancer patients from phase II portion of the study, presented at the 2017 Genitourinary Cancers Symposium.
- 14 Feb 2017 Results published in an Aeterna Zentaris media release.
- 14 Feb 2017 Results from this trial were presented at the 2017 Genitourinary Cancers Symposium, according to an Aeterna Zentaris media release.